Our data provide evidence that rapamycin (mTOR), particularly mTORC1, controls the glycolytic and oxidative profiles of human Sertoli cells. The mTOR signaling may be a pharmacologic target to control male reproductive potential.
Artificial oocyte activation with calcium ionophore does not cause a widespread increase in chromosome segregation errors in the second meiotic division. However, we recommend that it is applied selectively to patients with specific indications.
Nonidentifying summary data on cross-border reproductive care were considered important by responding Canadian Fertility and Andrology Society and Society for Assisted Reproductive Technology members. However, only one center from these societies was willing to collect and submit data.
Cancer survivors commonly experience amenorrhea, especially those who receive chemotherapy, are nulligravida, or are older at diagnosis. Most women resume menses within 2 years of diagnosis or not at all.
Differences in ovarian reserve between age-matched Bangladeshis who moved to London as children or adults highlight the influence of developmental environments rather than ethnicity on the tempo of reproductive aging.
Systematic change from norethindrone acetate to dienogest as first-choice progestin for endometriosis was associated with enhanced drug tolerability and similar improvement in pain relief, quality of life, and patient satisfaction.
The magnitudes of risk for early pregnancy loss after in vitro fertilization for all infertility diagnoses were small. The risks were similar when transferring similar quality embryos in fresh or frozen cycles.
Among a prospective cohort of women undergoing in vitro fertilization treatments at an academic fertility center, urinary methylparaben, propylparaben, and butylparaben concentrations were not associated with clinical in vitro fertilization outcomes.
The addition of growth hormone to the antagonist protocol in poor-responder women undergoing in vitro fertilization/intracytoplasmic sperm injection cycles resulted in better cycle outcomes but did not significantly affect pregnancy rates.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us